High-Dose Interleukin-2 (hd Il2) Armed with Pathology-Based Selection Criteria: a Real Option in Treatment of Metastatic Renal Cell Carcinoma (mrcc) after Targeted Therapy

Aim: HD IL2 as initial therapy in well-selected patients with mRCC can produce durable complete remissions rarely achieved by other therapies, but its efficacy and feasibility after VEGF-targeted therapies is less certain. Response rates (RR) in unselected patients has been reported as low and with excessive toxicity. We undertook a retrospective study of HD IL2 post-targeted therapy in our centre to assess its efficacy and toxicity, plus the impact of our previously reported pathology-based selection criteria.